What did the FDA actually do?

On March 3, 2026, the FDA announced 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites. The agency described it as the second group of warning letters sent to telehealth firms since it launched a crackdown on misleading direct-to-consumer pharmaceutical advertising in September. An earlier round of 25 letters was also reported.

Which claims does the FDA consider misleading?

The agency lists five: using website branding that falsely implies the telehealth company is the compounder; describing a compounded drug as a generic version of, or the same as, an FDA-approved drug; claiming a compounded drug is FDA-approved or has been evaluated for safety and effectiveness; describing a compounded drug as clinically proven to produce the same result as the approved drug; and claiming a compounded drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility.

Is a compounded drug the same as a generic?

No, and the FDA specifically flags this comparison as misleading. Generic drugs are approved by the FDA before marketing, following review of their safety, effectiveness, and quality. Compounded drugs are not reviewed by the agency at all before they are marketed. The two are regulated completely differently.

Can a pharmacy be "FDA-approved"?

No. The FDA states plainly that it "does not approve or license any facility." Any claim that a compounded medication comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility is on the agency's list of misleading claims. Facilities can register with the FDA and be inspected by it, but registration is not approval.

Why does it matter who compounds my medication?

Because the compounding pharmacy — not the telehealth company you bought from — actually made the product, and it is the entity whose sterility practices and quality controls determine what is in the vial. The FDA specifically flags branding that obscures this by putting the telehealth firm's own name on the product. In our reviews, no compounded provider we examined named its compounding pharmacy partners.

Does this mean compounded GLP-1s are unsafe?

It does not say that, and neither do we. The enforcement is about how these products are marketed, not a finding that any particular product harmed anyone. What it establishes is that regulators found widespread misrepresentation of what compounded medication is — which is a good reason to read marketing claims carefully rather than to panic.

GLP-1 Marketing Red Flags: The 5 Claims the FDA Says Are Misleading

Q: Has anyone been penalised over cancellations and refunds?

Yes. The Federal Trade Commission approved a final order against a telehealth provider where the firm and its principals were found to have failed to process cancellation and refund requests in a timely manner and failed to obtain express informed consent. That is a separate regulator from the FDA, addressing a separate problem — billing practices rather than medical claims.

What happened

On March 3, 2026, the FDA announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products offered on their websites. The agency described this as the second group of warning letters sent to telehealth firms since it launched a crackdown on misleading direct-to-consumer pharmaceutical advertising the previous September. An earlier round of 25 letters was also reported.

The scale is worth noting. The FDA stated that over the preceding six months it had sent thousands of letters warning pharmaceutical and telehealth firms to remove misleading ads — more than it had sent over the entire preceding decade.

“Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA's approval process.” — FDA Commissioner Marty Makary, M.D., M.P.H.

The FDA identified two primary violations in the letters: making claims implying sameness with FDA-approved products, and obscuring product sourcing by advertising products branded with the telehealth firm's own name or trademark without qualification, implying they are the compounder.

The five claims the FDA flags

Separately, the agency publishes a direct list of what telehealth companies should not say when marketing compounded GLP-1 drugs. Treat it as a checklist you can run against any provider's website in about two minutes.

Website branding that implies the telehealth company is the compounder

Putting the company's own name or trademark on the product, without qualification, obscures who actually made it. The FDA identified this as a primary violation in its March 2026 letters, describing it as "obscuring product sourcing."

Ask them: “Which pharmacy compounds this medication, and where is it located?”

Describing a compounded drug as a "generic version" of an approved drug

Generic drugs are FDA-approved before marketing. Compounded drugs are not reviewed at all. Calling one the other implies a level of oversight that does not exist.

Ask them: “Is this product FDA-approved, or is it compounded?”

Claiming the compounded drug is FDA-approved or FDA-evaluated

Compounded drugs are not reviewed by the agency for safety, effectiveness, or quality prior to marketing. Any claim otherwise is straightforwardly false.

Ask them: “Can you point me to the FDA approval for this specific product?”

"Clinically proven to produce the same result" as the approved drug

The trials were run on the approved product, not on a compounded preparation. Borrowing a brand-name drug's trial results for a compounded version is exactly the inference the FDA flags.

Ask them: “Which trial was run on this compounded product specifically?”

Claiming the drug comes from an "FDA-approved" or "FDA-licensed" pharmacy

The FDA does not approve or license any facility. Registration and inspection exist; approval of a facility does not. This phrasing borrows credibility the regulator has not granted.

Ask them: “Is the pharmacy registered with the FDA, and has it been inspected?”

Why the sourcing point matters most

Of the five, the branding one is the most consequential and the least obvious to a reader.

When a telehealth company puts its own name on a vial, the natural inference is that the company made it. Usually it did not. A separate compounding pharmacy prepared the medication, and that pharmacy's sterility practices, quality controls, and inspection history are what actually determine what you are injecting. The FDA calls this “obscuring product sourcing,” and it was one of the two primary violations cited in the March 2026 letters.

What we found in our own reviews

Not one of the compounded providers we reviewed names its compounding pharmacy partners. Not Mochi Health, Found, Eden, Zealthy, Henry Meds, Ivím Health, Fridays, Lemonaid, or Noom. Noom goes furthest, stating its products come from USP-compliant, state-regulated pharmacies — and still names none of them. We flagged this in every review before we found the FDA guidance, and the agency's position confirms it is worth asking about.

The billing side: the FTC

The FDA regulates medical claims. Billing practices are the Federal Trade Commission's territory, and it has been active here too.

The FTC approved a final order against a telehealth provider in which the firm and its principals were found to have failed to process cancellation and refund requests in a timely manner, and failed to obtain express informed consent.

That maps onto something we see constantly in this market. Several providers we reviewed either publish no cancellation terms at all, or attach their best prices to multi-month prepayments while leaving refund terms on an unsummarised linked page. Our Fridays review notes an explicit “all other fees are non-refundable” policy; LifeMD states membership fees already incurred are not refundable. Those are at least published. The ones that say nothing are the concern.

A practical checklist before you pay

Is the product FDA-approved or compounded? If the site is vague, that vagueness is itself the answer.
Who compounds it? Ask for the pharmacy name. A provider that will not tell you cannot be evaluated.
Does the site borrow trial results? STEP and SURMOUNT were run on Wegovy and Zepbound, not on a compounded preparation.
Does it use the word “generic”? Compounded drugs are not generics, and the FDA flags the comparison.
Does it claim FDA approval or licensure of a facility? The FDA does not approve or license facilities. Full stop.
Where are the cancellation and refund terms? Find them before you pay, particularly if the best price requires prepaying for months.
What does it cost after the introductory period? Most providers do not say. Walgreens and GoodRx Care both do.

What this does and does not mean

It would be easy to read enforcement news as evidence that compounded GLP-1s are dangerous. That is not what the FDA said, and it is not what we are saying. These letters concern marketing — how products were described — rather than findings that specific products harmed patients.

What the action does establish is that misrepresentation was widespread enough for the agency to send dozens of letters in two rounds, on top of thousands of letters across the wider pharmaceutical advertising crackdown. That is a reason to read claims carefully, ask direct questions, and treat a provider's willingness to answer them as information in itself.

For the regulatory picture on compounding more broadly — what changed when the FDA declared the shortages resolved, and the conditions under which compounding continues — see our brand-name versus compounded guide.

GLP-1 Marketing Red Flags